卡博桑提尼布治疗晚期肝细胞癌的最新实践:多中心回顾分析
Hiroaki Kanzaki1, Sadahisa Ogasawara2, Tomomi Okubo3
1Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan.
Drugs - real world outcomes
|July 19, 2023
概括
卡博桑提尼布在临床试验之外的高级肝细胞癌 (HCC) 患者中显示出有效性. 减少剂量可能会改善肝脏问题患者的治疗结果,延长治疗时间.
科学领域:
- 肝细胞癌 (HCC) 治疗方法
- 瘤学 药物有效性 药物有效性
- 癌症护理中的现实世界证据
背景情况:
- 在CELESTIAL试验中,卡博桑提尼布在索拉费尼布后的高级HCC中表现出有效性.
- 目前的HCC治疗趋势倾向于免疫疗法而不是分子药物.
- 卡博桑提尼布现在在现实实践中使用,不同于最初研究的环境.
研究的目的:
- 在现实临床环境中评估卡博桑提尼布在晚期HCC患者的安全性和有效性.
- 为了比较卡博赞提尼布在比CELESTIAL试验更广泛的患者群体中的结果.
- 探索剂量降低对治疗结果和不良事件的影响.
主要方法:
- 来自三家日本机构的回顾性数据收集 (2018年9月 - 2021年11月).
- 包括接受卡博赞提尼布的晚期HCC患者.
- 分析患者特征,治疗线路,肝功能 (Child-Pugh类) 和不良事件.
主要成果:
- 23名先进的HCC患者接受了卡博赞提尼布;21.7%的患者患有Child-Pugh B级,52.2%的患者接受了第四线或后期治疗.
- 无进展生存时间的中位数为3.7个月.
- 与60毫克相比,使用40或20毫克的初始剂量观察到较低的因不良事件而导致的中止率,特别是在Child-Pugh B或后期患者中. 继续治疗超过3个月的患者更有可能减少剂量.
结论:
- 卡博桑提尼布用于超出CELESTIAL试验标准的多样化的HCC患者群体.
- 剂量减少策略可能有利于肝功能受损的患者.
- 通过剂量调整来管理不良事件可能会延长卡博桑提尼布治疗的持续时间.
更多相关视频
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.4K
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.3K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
174
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
174